Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a Beta-3 adrenergic receptor agonist presented as an oral formulation for oral use. It relaxes detrusor smooth muscle, increasing bladder capacity and reducing involuntary contractions, and is indicated for the management of overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients.

GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global markets.

Mirabegron is used to treat conditions related to overactive bladder by targeting the beta‑3 adrenergic pathway. - Overactive bladder: reduces urgency and frequency by increasing bladder capacity. - Urinary urgency: diminishes the sudden need to void. - Urinary frequency: lowers the number of daily voids. - Urge urinary incontinence: decreases episodes of involuntary leakage.

Adverse reactions reported with Mirabegron Stada vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Headache: mild to moderate intensity. - Nasopharyngitis: symptoms of common cold. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Tachycardia: increased heart rate. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, consider the following precautions. - Renal impairment: assess renal function and adjust therapy if needed. - Hepatic impairment: evaluate liver function and monitor for adverse effects. - Cardiovascular disease: monitor blood pressure and heart rate regularly. - Concomitant antihypertensives: watch for additive blood pressure effects. - Drug interactions: review patient medication list for potential interactions. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Mirabegron may interact with several drug classes; monitor patients accordingly.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron plasma levels. - Antihypertensive agents (e.g., beta‑blockers): risk of additive blood pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): possible modest increase in exposure. - Diuretics: may affect electrolyte balance and blood pressure. - Anticholinergic drugs: monitor for additive urinary effects.